SCHEMBL1301837

SCHEMBL1301837

O=S(=O)(O)c1ccc(Br)c(Br)c1O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA4 P22748 2/20 0.34
CA6 P23280 2/20 0.34
COMT P21964 1/20 0.33
CYP1A2 P05177 1/20 0.33
LMNA P02545 1/20 0.33
PGAM1 P18669 1/20 0.33
AURKA O14965 1/20 0.33
AURKB Q96GD4 1/20 0.33
CTRB1 P17538 1/20 0.33
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
ALDH1A1 P00352 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
MAPT P10636 2/20 0.32
BLM P54132 2/20 0.32
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32
APEX1 P27695 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10424160 0.83 MEN1 (0.36) CA1CA2CA4CA6COMT
SCHEMBL9615691 0.82 CA2 (0.33) CA1CA2CA4CA6COMT
SCHEMBL31357038 0.82 CA2 (0.33) CA1CA2CA4CA6COMT
SCHEMBL28142426 0.79 MYC (0.38) COMTCYP1A2LMNAPGAM1AURKA
SCHEMBL5683924 0.78 PGAM1 (0.45) COMTCYP1A2LMNAPGAM1AURKA
SCHEMBL9312559 0.75 HSD17B10 (0.42) CA1CA2CA4CA6LMNA
SCHEMBL1070323 0.74 CA2 (0.45) CA1CA2CA4CA6CYP1A2
SCHEMBL6771382 0.73 CA2 (0.33) CA1CA2CA4CA6COMT
SCHEMBL22394908 0.72 MYC (0.35) CA1CA2CA4CA6CYP1A2
SCHEMBL11056133 0.72 TTR (0.37) CA1CA2CA4CA6AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180104185-A1 LIQUID COMPOSITIONS CAPABLE OF FOAMING AND INCLUDING ACTIVE AGENTS, AND METHODS FOR MAKING OR DEVELOPING SAME MIKA PHARMA GMBH 2018-04-19 US disclosed
US-9693956-B2 Liquid compositions capable of foaming and including active agents, and methods for making or developing same MIKA PHARMA GMBH 2017-07-04 US disclosed
EP-2387391-B1 METHOD FOR DEVELOPING A LIQUID COMPOSITION TO BE APPLIED TO THE SKIN AS A FOAM AND A COMPOSITION THAT CAN BE APPLIED TOPICALLY MIKA PHARMA GES FÜR DIE ENTW UND VERMARKTUNG PHARMAZEUTISCHER PRODUKTE MBH (DE) 2017-01-11 EP disclosed
US-20160022579-A1 Liquid Compositions Capable of Foaming and Including Active Agents, and Methods for Making or Developing Same MIKA PHARMA GMBH 2016-01-28 US disclosed
US-9005626-B2 Liquid compositions capable of foaming and including active agents, and methods for making or developing same MIKA PHARMA GMBH (DE) 2015-04-14 US disclosed
US-20110269704-A1 METHOD FOR DEVELOPING A LIQUID COMPOSITION TO BE APPLIED TO THE SKIN AS A FOAM AND A COMPOSITION THAT CAN BE APPLIED TOPICALLY MIKA PHARMA GESELLSCHAFT FUR DIE ENTWICKLUNG UND VERMARKTUNG PHARMAZEUTISCHER PRODUKTE MBH (DE) 2011-11-03 US disclosed
US-20110059117-A1 Liquid Compositions Capable of Foaming and Including Active Agents, and Methods for Making or Developing Same MIKA PHARMA GMBH (DE) 2011-03-10 US disclosed
US-20070010700-A1 Safety containers for biologically active substances and method for producing said container BAXTER INTERNATIONAL INC (US) 2007-01-11 US disclosed
EP-1585679-A1 SAFETY CONTAINERS FOR BIOLOGICALLY ACTIVE SUBSTANCES AND METHOD FOR PRODUCING SAID CONTAINER Baxter Healthcare S.A. (CH) 2005-10-19 EP disclosed
WO-2004063036-A1 SAFETY CONTAINERS FOR BIOLOGICALLY ACTIVE SUBSTANCES AND METHOD FOR PRODUCING SAID CONTAINER BAXTER HEALTHCARE S.A. (CH) 2004-07-29 WO disclosed